Immix Biopharma Announces Pricing of $125 Million Underwritten Common Stock Offering

Immix Biopharma, Inc. announced the pricing of an underwritten public offering of 11,363,637 shares of its common stock at a price of $11.00 per share. The company expects to raise approximately $125 million in gross proceeds, with net proceeds estimated at $117.1 million after deducting underwriting fees and other offering expenses.

Key Details

• Offering Terms: The company will issue and sell 11,363,637 shares of common stock at a public offering price of $11.00 per share.
• Financials: Gross proceeds are expected to be approximately $125 million, with estimated net proceeds of $117.1 million.
• Use of Proceeds: The net proceeds will be used to fund the development of its lead candidate NXC-201, as well as for working capital and general corporate purposes.
• Timeline & Underwriter: The offering is expected to close on or about September 30, 2026, with J.P. Morgan Securities LLC acting as the sole book-running manager.